Evidence map›Paper›PMID 38097279›Full record

ArticleESC heart failure2024

Trajectory change of left ventricular ejection fraction after rhythm control for atrial fibrillation in heart failure.

Jinping Si, Yuxi Sun, Lin Bai, Gary Tse, Zijie Ding, Xinxin Zhang, Yanli Zhang, Xuefu Chen, Yunlong Xia, Ying Liu

Abstract read
In one paragraph

Article in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jinping SiDepartment of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Yuxi SunDepartment of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Lin BaiDepartment of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Gary TseDepartment of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Zijie DingDepartment of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Xinxin ZhangDepartment of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Yanli ZhangDepartment of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Xuefu ChenDepartment of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Yunlong XiaDepartment of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Ying LiuDepartment of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.

Funding

National Natural Science Foundation of China 82170385National Natural Science Foundation of China U1908209
6 · The paper itself

Abstract

aimsRhythm control therapy has shown great benefits for patients with atrial fibrillation (AF) and heart failure (HF). However, few studies have evaluated the effects of rhythm control on left ventricular ejection fraction (LVEF) trajectory across the whole HF spectrum. Our study explored the prevalence and predictors of LVEF trajectory changes and their prognostic implications following rhythm control. METHODS AND

resultsDepending on the treatment strategy, the cohort was classified into rhythm and rate control groups. Alterations in HF types and LVEF trajectory were recorded. The observational endpoints were all-cause mortality and HF-related admission. Predictors of LVEF trajectory improvement in the rhythm control group were evaluated. After matching, the two groups had similar age [mean age (years): rhythm/rate control: 63.96/65.13] and gender [male: rhythm/rate control: n = 228 (55.6%)/233 (56.8%)]. Based on baseline LVEF measurement, the post-matched cohort had 490 HF with preserved ejection fraction (rhythm/rate control: n = 260/230; median LVEF: 58.00%/57.00%), 99 HF with mildly reduced ejection fraction (rhythm/rate control: n = 50/49; median LVEF: 45.00%/46.00%), and 231 HF with reduced ejection fraction (rhythm/rate control: n = 100/131; median LVEF: 32.50%/33.00%). Trajectory analysis found that the rhythm control group had a greater percentage of LVEF trajectory improvement than the rate control group [80 (53.3%) vs. 71 (39.4%), P = 0.012]. Cox regression analysis also showed that the rhythm control group was more likely to have improved LVEF trajectory compared with the rate control group {hazard ratio [HR] 1.671 [95% confidence interval (CI) 1.196-2.335], P = 0.003}. In the survival analysis, the rhythm control group experienced significant lower risks of all-cause mortality [HR 0.600 (95% CI 0.366-0.983), P = 0.043] and HF-related admission [HR 0.611 (95% CI 0.496-0.753), P < 0.001]. In the rhythm control subgroup, E/e' [odds ratio (OR) 0.878 (95% CI 0.792-0.974), P = 0.014], left ventricular end-diastolic diameter [OR 0.874 (95% CI 0.777-0.983), P = 0.024], and CHA2DS2-VASc score (congestive HF, hypertension, age ≥75 years, diabetes mellitus, stroke or transient ischaemic attack, vascular disease, age 65-74 years, and sex category) [OR 0.647 (95% CI 0.438-0.955), P = 0.028] were identified as three independent predictors of LVEF trajectory improvement.

conclusionsRhythm control is associated with improved LVEF trajectory and clinical outcomes and may thus be considered the optimal therapeutic strategy for patients with both HF and AF.

Indexed as

Atrial FibrillationHeart FailureStrokeVentricular Dysfunction, LeftAgedFemaleHumansMaleMiddle AgedStroke VolumeVentricular Function, LeftAtrial fibrillationHeart failureLeft ventricular ejection fractionRhythm controlTrajectory

Identifiers

PMID38097279
PMCPMC10966243

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.